MIRA PHARMACEUTICALS, INC.

For the period ended Mar 31, 2026. Filed May 14, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2026 · Filed May 14, 2026

MIRA$0.62+0.3%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Item 1. Condensed Consolidated Balance Sheets

CONDENSED CONSOLIDATED BALANCE SHEETS

	March 31,	December 31,
	2026	2025
(unaudited)
ASSETS
Current assets:
Cash	$4,815,031	$6,346,921
Prepaid expenses	21,748	28,146
Short-term investments	4,591,518	4,683,099
Total current assets	9,428,297	11,058,166
Related party receivable	35,439	35,439
Total assets	$9,463,736	$11,093,605
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Trade accounts payable and accrued liabilities	$34,008	$129,203
Accrued compensation – related party	80,753	242,258
Advance payable to related party	—	330,607
Total current liabilities	114,761	702,068
Total liabilities	114,761	702,068
Commitments and contingencies (Note 6)	-	-
Stockholders’ Equity
Preferred Stock, no par value, 10,000,000 shares authorized and none issued or outstanding.	—	—
Common Stock, no par value; 100,000,000 shares authorized, 42,022,087 and 41,938,587 shares issued and outstanding at March 31, 2026 and December 31, 2025, respectively.	4,202	4,194
Additional paid-in capital	50,075,131	49,967,549
Accumulated deficit	(40,730,358)	(39,580,206)
Total stockholders’ equity	9,348,975	10,391,537
Total liabilities and stockholders’ equity	$9,463,736	$11,093,605

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.